Table 3. Actionable alteration by sarcoma subtype.
| Histology (patients) | No reportable alteration, n (%) | Patients had alteration(s), but none actionable, n (%) | Patients with approved drug(s) in the disease available, n (%) (on-label) | Patients with approved drug(s) in another disease available, n (%) (off-label) | Patients with experimental treatment options (clinical trials), n (%) | Patients with pre-clinical treatment options, n(%) |
|---|---|---|---|---|---|---|
| LEIOMYOSARCOMA | 1 | 10 | 3 | 6 | 8 | 7 |
| DEDIFFERENTIATED LIPOSARCOMA | 0 | 0 | 11 | 10 | 10 | |
| OSTEOSARCOMA | 1 | 6 | 1 | 2 | 4 | 4 |
| WELL DIFFERENTIATED LIPOSARCOMA | 0 | 1 | 7 | 7 | 7 | |
| CARCINOSARCOMA | 0 | 3 | 5 | 6 | 6 | |
| RHABDOMYOSARCOMA | 1 | 1 | 2 | 5 | 5 | |
| GASTROINTESTINAL STROMAL TUMOR | 1 | 3 | 3 | 4 | 4 | |
| SPINDLE CELL SARCOMA | 1 | 1 | 2 | 4 | 3 | |
| SYNOVIAL SARCOMA | 1 | 2 | 0 | 1 | 1 | 1 |
| ALVEOLAR SOFT PART SARCOMA | 1 | 1 | 0 | 1 | 1 | 1 |
| CHONDROSARCOMA | 1 | 1 | 0 | 0 | 2 | 1 |
| CHORDOMA | 1 | 0 | 1 | 2 | 2 | |
| CLEAR CELL SARCOMA | 3 | 0 | 0 | 0 | 0 | |
| EWING SARCOMA | 2 | 0 | 1 | 1 | 1 | |
| UNCLASSIFIED | 1 | 0 | 1 | 2 | 2 | |
| ALVEOLAR RHABDOMYOSARCOMA | 2 | 0 | 0 | 0 | 0 | 0 |
| FIBROSARCOMA | 2 | 0 | 0 | 0 | 0 | |
| BRAIN GLIOSARCOMA | 0 | 0 | 1 | 1 | 1 | |
| DESMOPLASTIC SMALL ROUND CELL TUMOR | 0 | 0 | 1 | 1 | 1 | |
| PLEOMORPHIC SARCOMA | 0 | 1 | 1 | 1 | 1 | |
| MALIGNANT PERIPHERAL NERVE SHEATH TUMOR | 1 | 0 | 0 | 0 | 0 | |
| MYXOID LIPOSARCOMA | 0 | 0 | 0 | 1 | 1 | |
| 7 | 33 | 14 | 46 | 61 | 58 | |
| 6.86% | 32.35% | 13.73% | 45.10% | 59.80% | 56.86% |